Isofol receives approval of biomarker analysis patent and intention-to-grant patent application for study dose regimen in Europe
GOTHENBURG, Sweden, July 26, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced the European approval for a patent covering the clinical use of a biomarker analysis to detect cancer patients ability to respond to folate-based therapy cancer treatments and an intention-to-grant patent application for a patent covering the AGENT study dose regimen in Europe.The patent approved covering the clinical use of a biomarker analysis is valid until 2035 and was approved in the US in 2019. The dose regimen patent covering the claim of the use of